Senate Files

Bills

S. 1862 119th Congress

ORPHAN Cures Act

Latest action, May 22, 2025: Read twice and referred to the Committee on Finance. (text: CR S3119)

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

1 cosponsor

Sponsored by John Barrasso (Republican). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
1 D · 0 R
  • Democrat
  • Republican
  • Independent
1 senators cosponsoring

Referred to: Senate: Finance Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

39 clientsQ2 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

ACADIA PHARMACEUTICALS
6 reports
ALNYLAM PHARMACEUTICALS, INC.
LMH STRATEGIC SOLUTIONS
6 reports
ASTRAZENECA PHARMACEUTICALS LP
6 reports
EMD SERONO INC
6 reports
INCYTE CORPORATION
6 reports
IONIS PHARMACEUTICALS, INC.
LMH STRATEGIC SOLUTIONS
6 reports
TRAVERE THERAPEUTICS
6 reports
ALNYLAM PHARMACEUTICALS, INC.
TIBER CREEK GROUP
5 reports
LUNDBECK LLC
5 reports
ASTRAZENECA
TIBER CREEK GROUP
4 reports
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.)
TIBER CREEK GROUP
4 reports
BOEHRINGER INGELHEIM USA CORPORATION
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
4 reports
EMD SERONO, INC.
TIBER CREEK GROUP
4 reports
INCYTE CORPORATION
TIBER CREEK GROUP
4 reports
ALNYLAM PHARMACEUTICALS, INC.
SPLITOAK STRATEGIES LLC
3 reports
The top 25 of 45 clients, by reports
ClientLobbying firmReportsReports totalingFromToSenate
ACADIA PHARMACEUTICALS6$3.6MQ4 2025Q3 2026yes
ALNYLAM PHARMACEUTICALS, INC.LMH STRATEGIC SOLUTIONS6$0Q4 2025Q3 2026yes
ASTRAZENECA PHARMACEUTICALS LP6$8.6MQ4 2025Q3 2026yes
EMD SERONO INC6$4.5MQ4 2025Q3 2026yes
INCYTE CORPORATION6$3.0MQ4 2025Q3 2026yes
IONIS PHARMACEUTICALS, INC.LMH STRATEGIC SOLUTIONS6$0Q4 2025Q3 2026yes
TRAVERE THERAPEUTICS6$1.0MQ4 2025Q3 2026yes
ALNYLAM PHARMACEUTICALS, INC.TIBER CREEK GROUP5$0Q4 2025Q2 2026yes
LUNDBECK LLC5$750KQ4 2025Q3 2026yes
ASTRAZENECATIBER CREEK GROUP4$350KQ4 2025Q1 2026yes
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.)TIBER CREEK GROUP4$280KQ4 2025Q1 2026yes
BOEHRINGER INGELHEIM USA CORPORATIONBOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC4$3.5MQ4 2025Q3 2026yes
EMD SERONO, INC.TIBER CREEK GROUP4$0Q4 2025Q1 2026yes
INCYTE CORPORATIONTIBER CREEK GROUP4$0Q4 2025Q1 2026yes
ALNYLAM PHARMACEUTICALS, INC.SPLITOAK STRATEGIES LLC3$0Q4 2025Q3 2025yes
IONIS PHARMACEUTICALS, INC.3$370KQ4 2025Q3 2025yes
JAZZ PHARMACEUTICALS, INC.AVENUE SOLUTIONS3$0Q2 2025Q3 2026yes
JOHNSON & JOHNSON SERVICES, INC.SPLITOAK STRATEGIES LLC3$0Q4 2025Q3 2025yes
MERCK & CO. INC.THE NICKLES GROUP, LLC3$0Q4 2025Q3 2025yes
YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOWTIDAL BASIN ADVISORS, INC.3$10KQ4 2025Q3 2025yes
AMGENTHE NICKLES GROUP, LLC2$0Q2 2025Q3 2025yes
ASTELLAS PHARMA US, INC.TIBER CREEK GROUP2$0Q2 2025Q3 2025yes
CHIESI USA, INC.SPLITOAK STRATEGIES LLC2$0Q2 2025Q3 2025yes
DAIICHI SANKYO, INC.TIBER CREEK GROUP2$0Q2 2025Q3 2025yes
JOHNSON & JOHNSON SERVICES, INC.THE NICKLES GROUP, LLC2$0Q2 2025Q3 2025yes